(HECM--10) (McKiernan and Bavister, 2000) containing 10% fetal calf serum (Hyclone Laboratories Inc) at 37
• C in 5% CO 2 to allow embryo development. The Cleaved embryos with high quality at 2--cell to blastocyst were transferred into the oviduct of the matched recipient monkey as described (Niu et al., 2010; Chen et al., 2012b) . Parts of embryos at 8--cell to blastocyst were used to detect TALEN--induced efficacy and mutant sequence. In this study, 19 cynomolgus and 7 rhesus monkeys were used as surrogate recipient to
TALENs injected embryos, and typically, 3 embryos were transferred for each ET. The earliest pregnancy diagnosis was performed by ultrasonography about 20--30 days after
ET. Both clinical pregnancy and number of fetuses were confirmed by fetal cardiac activity and presence of a yolk sac as detected by ultrasonography (Chen et al., 2012b) .
The early in vitro development of the embryos appeared to be not substantially affected by the injection of TALENs, as 40% of the embryos injected with MeCP2 TALENs plasmid were able to develop to blastocyst stage. 21 rhesus embryos injected with TALENs were implanted into 7 surrogate mothers (see Figure 1B in main text). 54 cynomolgus embryos injected with TALENs were implanted into 19 surrogate mothers ( Figure 1B ).
Two rhesus foster mothers and 6 cynomolgus got pregnancy. Two rhesus foster mothers miscarried at 30 and 63/64 days of gestation. Both the aborted fetuses were male suggesting the miscarriage probably was caused by the MeCP2 knockout. One live--born female cynomolgus and one 92--day gestation miscarried male cynomolgus was observed.
Evaluation of TALEN--mediated mutagenesis in monkeys
To evaluate the targeting efficiencies of the TALENs, the PCR products corresponding to the target sites were amplified and sequenced from individual embryos in post--8--cell embryos including morula or blastocyst stage. A total of 46% (13/ T7EN1 cleavage assay and genomic DNA sequencing Different samples, including different tissues, placenta, umbilical cord, and skin tissues were collected and digested in lysis buffer (10 µM Tris--HCl, 0.4 M NaCl, 2 µM EDTA, 1%
SDS and 100 µg/ml Proteinase K). The genomic DNA was extracted from lysate by phenol--chloroform recovered by alcohol precipitation. The T7EN1 cleavage assay was performed as described (Shen et al., 2013) . In brief, targeted fragments were amplified by TaKaRa Ex Taq® Hot Start DNA polymerase (Takara, RR006B) from extracted DNA, and purified with Wizard® SV Gel and PCR Clean--Up System (Promega, A9285). Purified PCR product was denatured and reannealed in NEBuffer 2 (NEB) using a thermocycler.
PCR products were digested with T7EN1 (NEB, M0302L) for 30 min and separated by 2.5% agarose gel (see Figure 1D in main text) or 7.5% PAGE gel (others T7EN1 assay figures). PCR products with mutations detected by T7EN1 cleavage assay were sub--cloned into T vector (Takara, 3270). For each sample, colonies were picked up randomly and Sanger sequenced by M13--47 primer.
Plasmid integration and off--target analyses
Information on MECP2 targeting TALEN plasmids is provided in supplementary materials. Using TALEN plasmid--specific sequences as well as Fok1 sequences, we examined potential integration of these sequences in the genome of our MECP2 mutant monkey tissues, with positive and negative controls. PCR results demonstrate no genomic integration ( Figure S2A ). Although, unlike sequence/base--complementation based approaches such as CRIPR--Cas9, which is prone to erroneous targeting, TALEN recognizes its target sequence by "amino acid--nucleotide" pairing. Compared to CRISPR, TALEN is known to have much lower off--target actions, with several reports indicating no detected "off--target" actions (Ding et al., 2013; Ousterout et al.; . There are only few reported cases of TALEN off--target actions (Mussolino et al., 2011; Hockeymeyer et al., 2011; and Osborn et al., 2013) . To test the potential off target mutations in our study,
we used a genome--wide TALEN target site prediction tool named TALENoffer (Garu et al., 2013) . TALENoffer has successfully predicted 5 out of 6 reported off--target events in the literatures listed above therefore being probably one of the best predicting tools for TALEN "off--target" sites. We submitted 3 pairs of TALEN as well as all possible cross--pair combinations to the computational prediction. A total of 41 exonic loci (with TALENoffer score > --1.8), 68 intronic loci (with TALENoffer score > --1.6) and 5 intergenic loci (with TALENoffer score > --1.4) were identified as potential off--target sites (Supplementary table S1). DNA fragments around all of the potential "off--target" loci were PCR amplified from genomic DNA of paternal and maternal donors, surrogate mother, testes, and brains of the two miscarried fetuses, and then subjected to Sanger sequencing. A total of 798 alleles were sequenced and no mutations were detected (Table S1 ). To further investigate potential "off--target" events in other tissues, we genotyped the 41 exonic loci from 24 additional tissue samples of miscarried fetuses as well as the surviving female cynomolgus and her parents. An additional 984 PCR products were sequenced and again no mutations with confidence were detected (Table S1 ). In sum, a total of 1882 sequencings suggested no "off--target" effects beyond the targeted exon with our approach. 
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